Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
09 2020
Historique:
received: 18 03 2020
revised: 12 06 2020
accepted: 16 06 2020
pubmed: 24 7 2020
medline: 2 10 2021
entrez: 24 7 2020
Statut: ppublish

Résumé

Circulating tumor DNA (ctDNA) has potential as a basis for understanding the molecular features of a tumor non-invasively and for use as a diagnostic, prognostic, and disease-monitoring marker. The aim of this study was to evaluate the clinical roles of ctDNA in patients with endometrial cancer. Since Somatic Tumor-related ctDNA detected in plasma before surgery was associated with poorer oncologic outcome on univariate analysis in patients with endometrial cancer harboring

Identifiants

pubmed: 32699017
pii: ijgc-2019-001053
doi: 10.1136/ijgc-2019-001053
doi:

Substances chimiques

Circulating Tumor DNA 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1340-1346

Informations de copyright

© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: KH received a grant from Eisai

Auteurs

Daisuke Shintani (D)

Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.

Taro Hihara (T)

Tsukuba Research Laboratories, Eisai Inc. Ltd, Tsukuba, Ibaraki, Japan.

Aiko Ogasawara (A)

Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.

Sho Sato (S)

Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.

Akira Yabuno (A)

Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.

Kenji Tai (K)

Tsukuba Research Laboratories, Eisai Inc. Ltd, Tsukuba, Ibaraki, Japan.

Keiichi Fujiwara (K)

Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.

Keisuke Watanabe (K)

Tsukuba Research Laboratories, Eisai Inc. Ltd, Tsukuba, Ibaraki, Japan.

Kosei Hasegawa (K)

Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan koseih@saitama-med.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH